• TechCrunch
• CrunchBase
• More
  • TechCrunch Europe
  • TechCrunch France
  • TechCrunch Japan

Prexa Pharmaceuticals

edit

Prexa, founded in 2006, is developing oral small molecule monoamine reuptake inhibitors that act most potently at the dopamine transporter. By safely enhancing dopamine activity and, to a lesser extent norepinephrine activity, Prexa intends to improve upon current treatments for ADHD, depression and Parkinson’s disease.

Prexa’s proprietary compound portfolio consists of highly differentiated reuptake inhibitors with unique dopamine-preferring neurotransmitter selectivity profiles. Prexa’s lead compound, PRX-12251, is a triple reuptake inhibitor that blocks dopamine, norepinephrine and serotonin transporters. PRX-12251 is entering IND-enabling studies. Prexa’s mono and dual reuptake inhibitors are targeted for partnerships with leading biotechnology and pharmaceutical companies.

Milestones

edit

• 
  Prexa Pharmaceuticals added Ev (Evelyn) Graham as COO.
  Posted 4/29/11 at 5:59pm
• 
  Prexa Pharmaceuticals added Charlie Cohen as Chairman/CEO .
  Posted 4/29/11 at 5:59pm
• 
  Prexa Pharmaceuticals received $7M in Series B funding. (5/11/11)
  Posted 5/11/11 at 7:13pm via prexainc.com
• 
  Prexa Pharmaceuticals received $3.2M in Venture Round funding. (4/29/11)
  Posted 4/29/11 at 5:59pm via masshightech.com

Videos

Screenshots

edit

Sources

1. Prexa Pharma raises $3.2M to target ADHD, depression, Parkinson's (masshightech.com) [edit]
2. Prexa Pharmaceuticals Obtains $7.0 million in Series B Financing (prexainc.com) [edit]